CD276 and congenital rubella syndrome: Altogether, this supports the notion that B7H3.CAR EBVSTs target allogeneic myeloid cells in a B7-H3–dependent manner and by diminishing these primary cellular mediators of CRS, attenuate the risk of CRS associated with CAR T-cell therapy.